Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis.

Clinical Sarcoma Research Pub Date : 2018-08-23 eCollection Date: 2018-01-01 DOI:10.1186/s13569-018-0104-z
Wangzhao Song, Eva van den Berg, Thomas C Kwee, Paul C Jutte, Anne-Marie Cleton-Jansen, Judith V M G Bovée, Albert J Suurmeijer
{"title":"Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis.","authors":"Wangzhao Song,&nbsp;Eva van den Berg,&nbsp;Thomas C Kwee,&nbsp;Paul C Jutte,&nbsp;Anne-Marie Cleton-Jansen,&nbsp;Judith V M G Bovée,&nbsp;Albert J Suurmeijer","doi":"10.1186/s13569-018-0104-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We studied two cases of rare fibrous bone tumors, namely desmoplastic fibroma (DF) and low-grade central osteosarcoma (LGCOS) resembling desmoplastic fibroma (DF-like LGCOS). As the clinical presentation, imaging features and histopathology of DF and DF-like LGOS show much overlap, the objective of this study was to investigate the value of cytogenetic analysis, molecular pathology and immunohistochemistry in discrimination of these two mimickers.</p><p><strong>Case presentation: </strong>A mutation in <i>CTNNB</i> (S45F) and nuclear beta-catenin immunostaining were observed in DF. DF-LGCOS had amplification of <i>CDK4</i> and showed strong nuclear expression of CDK4 by IHC. Moreover, the karyotype of DF-LGCOS showed an interstitial heterozygous deletion of the long arm of chromosome 13 (q12q32), associated with loss of the <i>RB1</i> tumor suppressor gene.</p><p><strong>Conclusions: </strong>Karyotyping and molecular genetic analysis may contribute to a conclusive diagnosis.</p>","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"8 ","pages":"16"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-018-0104-z","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Sarcoma Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13569-018-0104-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

Background: We studied two cases of rare fibrous bone tumors, namely desmoplastic fibroma (DF) and low-grade central osteosarcoma (LGCOS) resembling desmoplastic fibroma (DF-like LGCOS). As the clinical presentation, imaging features and histopathology of DF and DF-like LGOS show much overlap, the objective of this study was to investigate the value of cytogenetic analysis, molecular pathology and immunohistochemistry in discrimination of these two mimickers.

Case presentation: A mutation in CTNNB (S45F) and nuclear beta-catenin immunostaining were observed in DF. DF-LGCOS had amplification of CDK4 and showed strong nuclear expression of CDK4 by IHC. Moreover, the karyotype of DF-LGCOS showed an interstitial heterozygous deletion of the long arm of chromosome 13 (q12q32), associated with loss of the RB1 tumor suppressor gene.

Conclusions: Karyotyping and molecular genetic analysis may contribute to a conclusive diagnosis.

Abstract Image

Abstract Image

Abstract Image

通过基因分析可将低级别中枢成纤维性骨肉瘤与其相似的结缔组织增生纤维瘤区分开来。
背景:我们研究了2例罕见的纤维性骨肿瘤,即结缔组织增生纤维瘤(DF)和类似结缔组织增生纤维瘤(DF样LGCOS)的低级别中央骨肉瘤(LGCOS)。由于DF和DF样LGOS的临床表现、影像学特征和组织病理学有很大的重叠,本研究的目的是探讨细胞遗传学分析、分子病理学和免疫组织化学在鉴别这两种拟态物中的价值。病例介绍:在DF中观察到CTNNB (S45F)突变和核β -连环蛋白免疫染色。DF-LGCOS具有CDK4扩增,免疫组化显示CDK4核强表达。此外,DF-LGCOS的核型显示13号染色体长臂(q12q32)的间质性杂合缺失,与RB1肿瘤抑制基因的缺失有关。结论:核型分析和分子遗传学分析有助于结论性诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
期刊介绍: Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信